Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil EC50 with Lidocaine or Sufentanil for Intubation
NCT07089173Recruiting
- Sponsor
- Peking University Shenzhen Hospital
- Start
- Aug 2025
- Primary completion
- Jul 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised trial in general anesthesia comparing Placebo Group, Sufentanil Group and Lidocaine Group (3 arms). Primary endpoint: Median Effective Effect-site Target Concentration (EC50) of Remifentanil. Started Aug 2025; status: recruiting.
02
Drugs
Lidocaine Hydrochloride Injection, without epinephrinesufentanil
03
Conditions
general anesthesia
Beyond the preview
Go deeper on NCT07089173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07089173.